Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-09-23Clinical Trial Update: Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) [Phase 4]
Phase 4 pediatric trial MK-0517-045 evaluates the safety of a three-day fosaprepitant regimen to prevent chemotherapy-induced nausea and vom…
-
FDA approval · 2021-09-01FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for ondansetron by Hospira, Inc., a generic antiemetic. Ondansetron is used to prevent postoperative…
-
FDA approval · 2021-09-01FDA Approved: ONDANSETRON — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved a supplemental application for ondansetron submitted by Qilu Pharmaceutical Co., Ltd. (ANDA 203711).
-
FDA approval · 2021-08-19FDA Approved: ONDANSETRON — Supplemental Application (Eugia US LLC)
FDA approved a supplemental ANDA from Eugia US LLC for ondansetron hydrochloride (ondansetron), establishing a generic product.
-
FDA approval · 2021-08-19FDA Approved: ONDANSETRON — Supplemental Application (Eugia US LLC)
FDA approves a supplemental application for ondansetron hydrochloride (Ondansetron) submitted by Eugia US LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-08-16FDA Approved: ONDANSETRON — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for ondansetron by Hikma Pharmaceuticals USA Inc., confirming the continued availability/approval of…
-
CLINICAL_TRIALS trial_result · 2021-08-04Clinical Trial Update: Evaluate Bioequivalence of Palonosetron (0.25mg/5mL) [Phase 4]
Phase 4 study evaluating bioequivalence of Palonosetron 0.25 mg per 5 mL for chemotherapy-induced nausea and vomiting prophylaxis has comple…
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer [Phase 3]
Phase 3 trial investigating aprepitant without steroid for preventing chemotherapy-induced nausea and vomiting in colorectal cancer patients…
-
FDA approval · 2021-07-29FDA Approved: FOSAPREPITANT — Original Application (NorthStar RxLLC)
FDA approved the original application for fosaprepitant dimeglumine (fosaprepitant) from NorthStar RxLLC to prevent chemotherapy-induced nau…
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer [Phase 4]
Phase 4 trial update investigating olanzapine for prevention and treatment of chemotherapy-induced nausea and vomiting in patients with lung…
-
FDA approval · 2021-06-29FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Avenacy, Inc.)
FDA approved palonosetron hydrochloride under an Original Abbreviated New Drug Application for Avenacy, Inc.
-
CLINICAL_TRIALS trial_result · 2021-06-25Clinical Trial Update: Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy [NA]
Clinical trial update on acupressure for controlling nausea in pediatric patients undergoing highly emetogenic chemotherapy; study completed…
-
CLINICAL_TRIALS trial_result · 2021-06-03Clinical Trial Update: Granisetron Transdermal Patch for Prophylaxis of Delayed CINV [Phase 3]
Phase 3 clinical trial update for granisetron transdermal patch intended to prevent delayed chemotherapy-induced nausea and vomiting (CINV).
-
FDA approval · 2021-06-02FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approves a supplemental application for AKYNZEO (netupitant and palonosetron) from Helsinn Therapeutics (U.S.), Inc.
-
FDA approval · 2021-06-02FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental indication for AKYNZEO (fosnetupitant and palonosetron) to prevent chemotherapy-induced nausea and vomiting in p…
-
FDA approval · 2021-03-03FDA Approved: FOSAPREPITANT — Original Application (Avenacy, LLC)
FDA approved the original application for Fosaprepitant (fosaprepitant dimeglumine) by Avenacy, LLC, a generic antiemetic indicated to preve…
-
CLINICAL_TRIALS trial_result · 2021-02-11Clinical Trial Update: Acupuncture for Chemotherapy-Induced Nausea and Vomiting [NA]
Clinical trial update on acupuncture for chemotherapy-induced nausea and vomiting has completed; results posted in 2021.
-
FDA approval · 2021-01-12FDA Approved: FOSAPREPITANT DIMEGLUMINE — Original Application (Eugia US LLC)
FDA approved the original application for fosaprepitant dimeglumine from Eugia US LLC, a generic NK1 receptor antagonist for preventing chem…
-
FDA approval · 2021-01-06FDA Approved: FOSAPREPITANT — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for Fosaprepitant from Fresenius Kabi USA, LLC under an ANDA.
-
FDA approval · 2020-12-23FDA Approved: APREPITANT — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for aprepitant submitted by Sandoz Inc.
-
FDA approval · 2020-12-09FDA Approved: FOSAPREPITANT — Original Application (Dr. Reddy's Laboratories Inc.,)
FDA approved the original application for fosaprepitant from Dr. Reddy's Laboratories, granting a generic formulation of the antiemetic used…
-
CLINICAL_TRIALS trial_result · 2020-12-07Clinical Trial Update: PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting [Phase 2]
Phase 2 PK/PD study in pediatric patients evaluating netupitant and palonosetron for prevention of chemotherapy-induced nausea and vomiting;…
-
FDA approval · 2020-10-27FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for AKYNZEO (fosnetupitant and palonosetron) from Helsinn Therapeutics (U.S.), Inc.
-
FDA approval · 2020-10-21FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for palonosetron hydrochloride by Sandoz Inc under ANDA 202521. The approval confirms the generic pr…
-
FDA approval · 2020-10-21FDA Approved: APREPITANT — Original Application (Golden State Medical Supply, Inc.)
FDA approved the original application for aprepitant, granting a generic version of this antiemetic to expand access.